CN111643631A - A health-preserving medicinal preparation and its processing method - Google Patents
A health-preserving medicinal preparation and its processing method Download PDFInfo
- Publication number
- CN111643631A CN111643631A CN202010718655.8A CN202010718655A CN111643631A CN 111643631 A CN111643631 A CN 111643631A CN 202010718655 A CN202010718655 A CN 202010718655A CN 111643631 A CN111643631 A CN 111643631A
- Authority
- CN
- China
- Prior art keywords
- decoction
- health
- ginseng
- water
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 238000003672 processing method Methods 0.000 title abstract description 6
- 241000208340 Araliaceae Species 0.000 claims abstract description 67
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 67
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 67
- 235000008434 ginseng Nutrition 0.000 claims abstract description 67
- 239000003814 drug Substances 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 44
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 29
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 23
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 16
- 241000234435 Lilium Species 0.000 claims abstract description 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 15
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 5
- 238000007873 sieving Methods 0.000 claims abstract description 4
- 238000010298 pulverizing process Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 34
- 230000036541 health Effects 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 20
- 238000012545 processing Methods 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010011224 Cough Diseases 0.000 abstract description 28
- 210000004185 liver Anatomy 0.000 abstract description 17
- 230000007774 longterm Effects 0.000 abstract description 13
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 9
- 201000005917 gastric ulcer Diseases 0.000 abstract description 9
- 208000011580 syndromic disease Diseases 0.000 abstract description 9
- 208000007882 Gastritis Diseases 0.000 abstract description 8
- 208000023652 chronic gastritis Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000002512 chemotherapy Methods 0.000 abstract description 7
- 230000001476 alcoholic effect Effects 0.000 abstract description 6
- 208000013116 chronic cough Diseases 0.000 abstract description 6
- 235000005911 diet Nutrition 0.000 abstract description 6
- 238000001959 radiotherapy Methods 0.000 abstract description 6
- 208000007848 Alcoholism Diseases 0.000 abstract description 5
- 201000007930 alcohol dependence Diseases 0.000 abstract description 5
- 208000023819 chronic asthma Diseases 0.000 abstract description 5
- 230000002980 postoperative effect Effects 0.000 abstract description 5
- 230000003750 conditioning effect Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 230000000378 dietary effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 71
- 210000002784 stomach Anatomy 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 210000000952 spleen Anatomy 0.000 description 30
- 210000004072 lung Anatomy 0.000 description 24
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 210000002216 heart Anatomy 0.000 description 18
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 17
- 229960004949 glycyrrhizic acid Drugs 0.000 description 17
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 17
- 235000019410 glycyrrhizin Nutrition 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 239000004378 Glycyrrhizin Substances 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 230000001976 improved effect Effects 0.000 description 15
- 235000012054 meals Nutrition 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 206010013781 dry mouth Diseases 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 235000009508 confectionery Nutrition 0.000 description 12
- 206010016256 fatigue Diseases 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- 230000007958 sleep Effects 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 11
- 229930182494 ginsenoside Natural products 0.000 description 11
- 229940089161 ginsenoside Drugs 0.000 description 11
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 10
- 230000035622 drinking Effects 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229960003720 enoxolone Drugs 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 206010008479 Chest Pain Diseases 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 206010033557 Palpitations Diseases 0.000 description 8
- 230000036528 appetite Effects 0.000 description 8
- 235000019789 appetite Nutrition 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 230000002269 spontaneous effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000035922 thirst Effects 0.000 description 8
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 7
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 7
- 208000006083 Hypokinesia Diseases 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 206010061428 decreased appetite Diseases 0.000 description 7
- 238000001784 detoxification Methods 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 229940010454 licorice Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000002398 materia medica Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 206010028813 Nausea Diseases 0.000 description 5
- 240000007594 Oryza sativa Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- -1 panaxadiol saponin Chemical class 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- 241001127714 Amomum Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229930194248 Licoflavone Natural products 0.000 description 4
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229940060184 oil ingredients Drugs 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000010415 tropism Effects 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
- 244000141331 Amomum villosum Species 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010017999 Gastrointestinal pain Diseases 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010062519 Poor quality sleep Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 208000026500 emaciation Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000003337 fertilizer Substances 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- LPLVUJXQOOQHMX-MOGLOQIBSA-N (2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-MOGLOQIBSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 241001248531 Euchloe <genus> Species 0.000 description 2
- 208000032139 Halitosis Diseases 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 2
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 description 2
- DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 2
- 229960001660 histamine phosphate Drugs 0.000 description 2
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 2
- 235000008718 isoliquiritigenin Nutrition 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 2
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- MOCOXAJEZKHXSF-IHMBCTQLSA-M sodium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MOCOXAJEZKHXSF-IHMBCTQLSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 description 1
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- RMGUNXLDOFELHW-UHFFFAOYSA-N 2-aminoacetic acid;oxalic acid Chemical compound NCC(O)=O.OC(=O)C(O)=O RMGUNXLDOFELHW-UHFFFAOYSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 1
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 1
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 208000010454 Experimental Liver Neoplasms Diseases 0.000 description 1
- 239000009517 FM 100 Substances 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010024552 Lip dry Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- LYJABSHZWWRJQW-UHFFFAOYSA-N OC1=CC=CC=C1.OC1=CC=CC=C1.OC1=CC=CC=C1.[AsH3] Chemical compound OC1=CC=CC=C1.OC1=CC=CC=C1.OC1=CC=CC=C1.[AsH3] LYJABSHZWWRJQW-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 206010042727 Swollen tongue Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241001502500 Trichomonadida Species 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- DAXQXVQJVFIVGT-UHFFFAOYSA-L [Na+].[Na+].C(CCC(=O)[O-])(=O)[O-].[Na+].[Na+] Chemical compound [Na+].[Na+].C(CCC(=O)[O-])(=O)[O-].[Na+].[Na+] DAXQXVQJVFIVGT-UHFFFAOYSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 208000023505 abnormal feces Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940115079 agri-cillin Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 229940045511 barium chloride Drugs 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 208000024753 bloody sputum Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- OEBRKCOSUFCWJD-UHFFFAOYSA-N dichlorvos Chemical compound COP(=O)(OC)OC=C(Cl)Cl OEBRKCOSUFCWJD-UHFFFAOYSA-N 0.000 description 1
- 229950001327 dichlorvos Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000040 effect on leukemia Effects 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229940029988 ginseng preparation Drugs 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000021142 long-term diet Nutrition 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 206010026820 marasmus Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000018962 mouth sore Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005088 urethane Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of medicines, and particularly relates to a health-preserving pharmaceutical preparation which comprises the following components in parts by weight: 15-30 parts of ginseng, 20-50 parts of lily, 10-40 parts of fructus amomi and 15-30 parts of liquorice. The invention also relates to a processing method of the health-preserving medicinal preparation, which comprises the following steps: (1) respectively pulverizing Ginseng radix and fructus Amomi, and sieving with 400 mesh sieve to obtain Ginseng radix powder and fructus Amomi powder; (2) decocting Bulbus Lilii and Glycyrrhrizae radix in water to obtain decoction; (3) concentrating the medicinal juice obtained in the step (2) into an extract, adding the ginseng powder and the fructus amomi powder obtained in the step (1), uniformly mixing, and drying at low temperature to obtain the granular medicine, namely the health-preserving medicinal preparation. The health-preserving medicinal preparation obtained by the scheme is suitable for long-term dietary therapy conditioning of people with tumor postoperative radiotherapy and chemotherapy, diabetes type II, chronic cough and asthma, long-term stay-up sub-health syndrome, chronic gastritis, gastric ulcer, alcoholism and alcoholic liver.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a health preserving pharmaceutical preparation and a processing method thereof.
Background
The aging degree of the national social population is getting more and more serious, and various chronic diseases are gradually increased under the influence of a plurality of factors such as diet, unhealthy life style, high-tension mental stress, long-term heavy physical energy overdraft, environmental pollution and the like. Therefore, some health preserving medicines or health products are gradually receiving attention. The existing health-care products in the market comprise: brain platinum for improving human sleep and regulating intestinal function; dongpeng special drink and red cattle for supplementing energy and resisting fatigue of human body; wanglaoji, Jiaduobao and Zhengzheng for clearing heat and purging fire; pine pollen capsule for improving immunity.
However, the health-care products are only suitable for daily eating by people and do not have specific curative effects on certain diseases, so that research and development of an innovative health-care product which is both disease-free and disease-treated is needed.
The technology is a six-generation health-preserving empirical prescription of traditional Chinese medicine based on the theory of 'simultaneous treatment of different diseases' of traditional Chinese medicine, and the essential reasons of the human body harmony diseases are that vital qi is insufficient, pathogenic qi can dry, and spleen and lung functions are weak, so that qi and blood disorder is caused, the congenital exhaustion of kidney-yin and kidney-yang cannot be timely supplemented, and heart and liver are affected, and even five viscera are damaged. Only natural ecological medicine-food homologous materials integrating the spiritual activities of heaven and earth and the lusterless days and months are adopted to fundamentally supplement yin-yang imbalance of the organism, promote the organism to return to the five internal organs to generate mutually and achieve the state of balancing qi, blood and yin and yang.
The health product of the technology has effective body conditioning effect on people who suffer from tumor postoperative radiotherapy and chemotherapy, diabetes type II, chronic cough and asthma, long-term stay up sub-health syndrome (drowsiness and hypodynamia, dry mouth, aphtha, inappetence, facial acne, color spots, dry skin and pruritus, female menstrual disorder, male alopecia, sexual hypofunction and the like), chronic gastritis, gastric ulcer, alcoholism and alcoholic liver, relieves health injury caused by chronic diseases, improves the happy life quality of people, and realizes healthy Chinese targets.
Disclosure of Invention
The invention aims to provide a health-preserving pharmaceutical preparation which has accurate indication by syndrome differentiation, simple and reasonable formula, clinical application for more than one hundred years and effective prescription proved by full and deep research of modern pharmacology, and has the functions of supplementing qi, nourishing yin, promoting the production of body fluid, strengthening spleen and resolving dampness.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows: a health preserving pharmaceutical preparation is composed of the following components in parts by weight: 15-30 parts of ginseng, 20-50 parts of lily, 10-40 parts of fructus amomi and 15-30 parts of liquorice.
By adopting the technical scheme of the invention, ginseng has the effects of tonifying qi, promoting the production of body fluid, quenching thirst, tonifying spleen and lung, controlling the deficiency of qi of the five internal organs, tonifying the conservative spirit of the six internal organs, producing blood with sweet and warm properties to tonify the ginseng, promoting the growth of yin and blood, strengthening the body resistance and tonifying qi and blood; the lily is sweet in taste and slightly cold, can clear heat in upper jiao, enters heart and lung to moisten lung and relieve cough, clears heart and soothes nerves and is mutually reinforced with ginseng as the ministerial drugs; fructus amomi is pungent in flavor and warm in property, enters the channels of the spleen and the stomach, and the spleen, the lung and the kidney are grown mutually, so that the fructus amomi is capable of tonifying the lung and the kidney, regulating primordial qi, activating qi, regulating the middle warmer, resolving dampness of alcohol food, activating the spleen, nourishing the stomach and assisting the acquired health and transportation of all things; the liquorice is sweet in taste and neutral in nature, and is used for removing cold and heat pathogenic qi of internal organs of the heart, the spleen and the stomach, relieving healthy qi, nourishing yin and blood, strengthening bones and muscles, tonifying spleen and stomach and growing muscles, moistening lung and strengthening strength, treating sore pain of incised wound and harmonizing and detoxifying. The Chinese medicinal composition has the effects of invigorating qi and blood and balancing yin and yang. The acquired resources can nourish the congenital roots, and the effects of losing weight and prolonging life are achieved for a long time. The health tea is suitable for patients with radiotherapy and chemotherapy period after tumor operation, diabetes type II, chronic cough and asthma, long-term sub-health syndrome, chronic gastritis, gastric ulcer, alcoholism and alcoholic liver. It is indicated for chronic deficiency of both qi and yin, qi deficiency and blood stasis, deficiency of both spleen and lung, deficiency of both heart and spleen, and disharmony between spleen and stomach.
The invention also aims to provide a processing method of the health-preserving medicinal preparation.
In order to achieve the purpose, the invention adopts the technical scheme that: a processing method of the health-preserving medicinal preparation comprises the following steps:
(1) respectively pulverizing Ginseng radix and fructus Amomi, and sieving with 400 mesh sieve to obtain Ginseng radix powder and fructus Amomi powder;
(2) decocting Bulbus Lilii and Glycyrrhrizae radix in water to obtain decoction;
(3) concentrating the medicinal juice obtained in the step (2) into an extract, adding the ginseng powder and the fructus amomi powder obtained in the step (1), uniformly mixing, and drying at low temperature to obtain the granular medicine, namely the health-preserving medicinal preparation.
According to the scheme, the ginseng and the fructus amomi are pulverized and sieved to obtain the medicinal powder, compared with the traditional decocting mode, the effective ingredients in the medicine are reserved to the maximum extent, the loss of precious and fine medicinal materials is reduced, and the resources and the cost are saved; the effective components can be fully dissolved out by decocting the lily and the liquorice; the obtained health promotion medicinal preparation is suitable for long-term diet therapy conditioning of tumor postoperative radiotherapy and chemotherapy period, diabetes type II, chronic cough and asthma, long-term stay up sub-health syndrome, chronic gastritis, gastric ulcer, alcoholism and alcoholic liver.
Specifically, in the step (1), before the ginseng and the fructus amomi are crushed, washing and drying are carried out. After being washed and dried, the ginseng and the villous amomum fruit are respectively subjected to superfine grinding and sieving treatment, thereby being beneficial to keeping natural active ingredients and volatile oil ingredients without being damaged and lost, improving the human bioavailability of the active ingredients of the medicine, reducing the loss of precious and fine medicinal materials, saving resources and cost and improving the health-care food effect.
In the step (2), before the decoction in water, the lily and the liquorice are soaked in water for 2-4 hours, and the water adding amount is 4-6 times of the total mass of the lily and the liquorice. In the process of soaking the medicinal materials, water can be fully absorbed into the medicinal materials, so that the first time can shorten the decoction time, and the second time can ensure that water-soluble components in the medicinal materials can be fully dissolved out during decoction.
The earthen jar is used as a decocting container, water is not required to be added in the decocting process, and the medicinal materials are soaked and the water is added for decocting. In the decocting process, the decoction is decocted for 1-1.5 hours by slow fire, the decoction is stopped when the amount of the decoction is 10-20% of the amount of the added water for decoction, and the decoction is separated. The earthen jar fired by the traditional method for decocting the medicines can ensure that the medicines are heated uniformly during decoction, the decoction effect is better, and the effective components can be protected to the maximum extent. Decocting the decoction with slow fire: firstly, the rapid reduction of the solution amount caused by overhigh temperature and large water evaporation amount in the decoction process is prevented, and the dissolution rate of effective components in the medicine (volume quality) is reduced; secondly, the loss of volatile components in the medicine is less when the medicine is decocted by slow fire than when the medicine is decocted by high temperature, so that the effective components of the medicine can be retained to the maximum extent.
Wherein the decoction is water obtained by soaking. In the soaking process, when the medicine absorbs water, some soluble components in the medicine can be dissolved out, in order to avoid the loss of the effective components of the medicine, the soaking process can be directly carried out in a decocting container, the medicine is directly heated and decocted after being soaked, and the waste of the effective components caused by the repeated transfer of the medicine and the medicine juice is also avoided.
The decocting process is carried out twice, after the first decocting is finished and the decoction is separated out, 4-6 times of water by mass is added into the medicine residues, the decocting process is repeated, and the decoction separated out for the second decocting is mixed with the decoction obtained by the first decocting. Therefore, the effective components in the medicine can be fully dissolved out, meanwhile, the effective components of the rhizome type traditional Chinese medicinal materials can be fully dissolved out, the active components of the medicine can be protected to the maximum extent, and the content of the effective components of the medicine juice can be improved.
Mixing the decoction, boiling with strong fire, concentrating to obtain extract, adding superfine Ginseng radix powder and fructus Amomi powder, mixing, and vacuum drying at 50 deg.C to prevent destruction of effective bioactive components and loss of volatile effective components, which affect dietetic therapy effect. Finally, preparing the granular preparation, namely the health-preserving medicinal preparation product.
In the process of processing and preparing the health-preserving medicinal preparation, the solid preparation is obtained without adding excipients and flavoring agents. In order to adapt to the fast-paced life of modern people, the medicine juice is concentrated and mixed with superfine powder to obtain a solid preparation, and the solid preparation is easy to store and carry for a long time. The medicine juice is extracted and refined by a conventional water extraction and alcohol precipitation method or an alcohol extraction and water precipitation method in the field to obtain the effective active ingredients of the health-care medicine for supplementing qi, nourishing yin, promoting the production of body fluid, strengthening spleen and resolving dampness. The active ingredients can also be combined with pharmaceutically acceptable carriers or excipients and flavoring agents into various pharmaceutical dosage forms, such as oral liquid, paste, granules, etc.
Detailed Description
The technical solution of the present invention is further described below with reference to examples.
First, pharmacological research
(one) Ginseng radix
1 traditional medicine property
1.1 the properties, flavor and meridian tropism
Sweet, slightly bitter and warm in nature. It enters spleen and lung meridians.
1.2 functional mechanism:
1.2.1 invigorating spleen and benefiting lung
The related works are common in all generations. The treatise on the herb properties: ginseng is used for treating deficiency of five internal organs, fatigue, impairment of deficiency, emaciation, regurgitation, emesis, abdominal distention, and mental retention. Title of "medical enlightenment source": ginseng, radix Ginseng, for the treatment of insufficiency of spleen-stomach yang-qi, shortness of breath, scanty qi, and tonifying middle-jiao and slow-jiao … …, is called Ben Cao Jing Shu (herbal Jing Shu): "true qi is deficient in the interior, so it is cold in the stomach and intestines, but not cold in the case of vigorous qi returning to yang , … … regulates middle energizer, and spleen tonifies it, it regulates middle energizer automatically ".
1.2.2 promoting the production of body fluid to quench thirst
Zhang element in the "Yi Xue Yuan" (self-source of medicine) and "Zhen Zhu Sac" (Pearl bag) both the characters of ginseng for quenching thirst and promoting the production of body fluid are recorded. The "Ben Cao Jing Shu" (Ben Cao Jing Shu) discusses the mechanism of action of Ginseng in this respect from the relationship between qi and yin and fluid: for diabetes, the qi returning will produce body fluid, and the body fluid will self-stop thirst .
1.2.3 benefiting qi, nourishing blood, promoting blood circulation
The book materia medica Zheng (materia medica treatment) says: for ginseng, both qi deficiency and blood deficiency can tonify … … collapse of yin and blood, and this failure is … … after the burst has occurred, which is sweet and pure in taste, so it can tonify blood. Li Dongyuan in the theory of spleen and stomach, discussed the mechanism of blood generation of Ginseng based on the theory of generation of qi and blood: it is sweet and warm, and can produce blood, but not blood. B, marking: the middle energizer is the method of tonifying blood with the ginseng, and yang hyperactivity can generate yin and blood, while the middle energizer is the method of tonifying blood with the ginseng, and the blood cannot be generated by itself, so yang qi generation is required to generate the yang qi, yang growth is the method of yin growth, and blood is vigorous . The famous physicians' book clearly records the characters of ginseng for promoting blood circulation, breaking hard mass and keeping people forget.
1.2.4 about the actions of Ginseng radix in removing heat due to its sweet and warm nature, discussion of Lidongyuan is first: ginseng, radix astragali and radix Glycyrrhizae are sweet and warm in nature, and are herbs for relieving high fever, purging yin fire, tonifying primordial qi and also for treating sore house holy.
2 modern pharmacological research
2.1 Effect on the Central nervous System
2.1.1 the regulating action on the excitation and inhibition of the central nervous system can not only improve the excitation process of the brain, but also improve the inhibition process, so that the inhibition tends to concentrate, the differentiation is more complete, and the excitation and inhibition processes are restored to balance.
2.1.2 enhancing the learning and memory function, the ginseng promotes the synthesis and release of acetylcholine in the central nervous system, increases the content of DA and NA in the brain, promotes the synthesis of RNA and protein in the brain, and improves the blood supply and oxygen supply of the brain, which is the pharmacological basis of ginseng intelligence development.
2.2 anti-ageing action
2.2.1 Life-prolonging action
The ginseng flower is used for breeding bees, so that the service life of the bees is obviously prolonged by 10-15 days. The ginseng injection of 15-16 mug/ml can obviously promote the in vitro culture of human embryo lung diploid SL7The growth and proliferation capacity of the strain fibroblast and the service life of the cell can be prolonged; CLMR (clMR) for human embryo diploid fiber cell-90、WI-38The life of the cells in the test tube is obviously prolonged by carrying out subculture.
2.2.2 effects on anti-peroxidation of cells and scavenging free radicals
The maltitol contained in Ginseng radix can combine with free radicals in vivo, inhibit lipid peroxidation of ethanol in mouse liver, and reduce accumulation of age-increasing pigment and lipofuscin. Therefore, the cell peroxidation resisting and free radical scavenging effects of the ginseng are part of the anti-aging effects of the ginseng.
2.3 enhancing the adaptability of the body
2.3.1 Regulation of the entire organism
Ginsenoside can obviously improve CAMP level of yang deficiency animals, reduce CGMP level, and increase CAMP/CGMP ratio. The ginsenoside also has regulating effect on the integration function of endocrine system, which indicates that the ginseng has obvious regulating effect on the adaptability of organism.
2.3.2 anti-stress Effect
Can obviously improve60Tolerance of CO-irradiated miceAnd has obvious protection effect on damage of adrenal gland function and immune function caused by long-term microwave irradiation of mice.
2.3.3 anti-fatigue Effect
Ginsenoside can increase the ability of brain cells in lower part of rat to bind cortisol by several times to several hundred times. The combination of brain cells and cortisol can improve the selection ability and discrimination ability of the body; the brain cells combine with ACTH to enhance the motor function and the arousal response of the brain, both of which can make the body generate temporary activity and comfort, thereby playing the role of anti-fatigue.
2.3.4 anti-mutational Effect
The ginseng polysaccharide has obvious inhibition effect on the increase of mouse bone marrow hyperphagia erythrocyte microsome due to chromosome aberration rate caused by X-ray irradiation and sister chromosome exchange caused by cyclophosphamide, the panaxadiol saponin can obviously reduce the aberration rate of male rat germ cell sperms, and the anti-mutation effect of ginseng is also one of mechanisms of prolonging the life of organisms.
2.4 Effect on immune function
2.4.1 enhancing phagocytic function of reticuloendothelial system, and restoring the inhibition of cyclophosphamide-induced leucopenia, macrophage phagocytic function, hemolysin formation and delayed allergy to normal level.
2.4.2 enhancing the immune function of cells, the ginsenoside Rd has obvious antagonism on spleen and thymus atrophy, T lymphocyte reduction and lymphocyte softening function reduction caused by prednisolone acetate. The panaxan and ginsenoside have certain protective effect on immunity damage caused by radioactive rays.
2.4.3 promoting the formation of specific antibody, ginseng has obvious enhancement effect on the generation of antigen-stimulated animal antibody, and ginseng and its extract ginsenoside are not only immunopotentiators, but also immunomodulators.
2.5 Effect on endocrine
2.5.1 Effect on protein and nucleic acid metabolism
Ginseng radix has effect in promoting synthesis of brain protein RNA and DNA, and ginsenoside Rg1Can not be atThe low concentration or the high concentration can increase the protein content in the brain of the mouse.
2.5.2 Effect on sugar metabolism
The panaxan A, B, C, D, E, U, T, S, O separated from Ginseng radix is effective in lowering blood sugar, wherein panaxan U has strongest effect. The acidic polypeptide composed of adenosine and 14 amino acids in ginseng root can resist the action of adrenalin, ACTH and glucagon, enhance the effect of insulin on sugar metabolism and inhibit the action of insulin for converting glucose into fat.
2.5.3 hypolipidemic Effect
The blood fat reducing function of ginseng is related to that ginseng can promote lipid metabolism and influence synthesis, decomposition, transformation and excretion of cholesterol and lipoprotein in blood.
2.6 antitumor Effect
2.6.1 cancer suppressing action
The ginseng contains various saponins, polysaccharides and volatile oil, which have anti-tumor effect. Ginsenoside for treating mouse sarcoma S of Morris hepatoma generation 25 mouse180ginsenoside-Rh2For promyelocytic leukemia HL-60 tumor strain, Morris tumor strain, mouse spontaneous melanoma, cervical cancer Hela cell, ginseng stem and leaf total saponin gastric tumor cell, and sarcoma S180Etc. all have different degrees of inhibitory effect. After long-term administration of Ginseng radix Rubri (processed product of Ginseng radix) extract, it has different degrees of inhibiting effect on carcinogenesis of chemical substances such as urethane, N-methyl-N-nitroso-N-nitro-arc, and aflatoxin, so that carcinogenesis rate of above substances is reduced significantly, and growth of above substances can be inhibited.
2.6.2 synergistic synergism on antitumor Agents
Ginseng radix has antitumor, anticancer effects, and is also synergist of antitumor drug, and Ginseng radix extract can enhance Fe-gabur anticancer effect, and Fe-gabur can be used together with Ginseng radix extract to significantly improve survival rate of mouse, and is used for S of mouse180The growth of sarcoma is also inhibited. Ginseng radix and cyclophosphamide are used together to produce obvious antitumor synergistic effect.
2.6.3 relieving side effects of anticancer drugs
The ginsenoside preparation has effect in relieving toxicity of anticancer drugs. The cephalotaxone, homoharringtonine and adriamycin are anticancer drugs with bone marrow and heart inhibiting effect. The compound preparation containing ginsenoside, oleanolic acid, anisole, small cephalotaxine and homoharringtonine has obvious treatment effect on leukemia and obviously weakens the toxic reaction of cephalotaxine on heart and hematopoietic organs. After the ginseng preparation is taken by a patient with tumor, the damage symptom of the chemotherapy drug to the organism can be obviously relieved, the bone marrow inhibition can be relieved, and the symptom can be relieved.
2.7 hypoglycemic action
Ginseng radix polypeptide, polysaccharide and saponin all have effects of lowering blood sugar. The ginseng polypeptide has the functions of reducing blood sugar, promoting glycogen decomposition, inhibiting synthesis of glycogen by lactic acid, activating activity of succinic acid dehydroacid (SDH) and CCH, and enhancing aerobic oxidation of sugar. The hypoglycemic effect of ginseng polysaccharide may be related to its activity in inhibiting lactic acid dehydrogen acid, succinic acid dehydrogen acid and cytochrome oxydic acid.
2.8 Effect on digestive System
2.8.1 enhancing the detoxifying power of the liver
The ginseng can shorten the anesthesia time of the ethanol to rabbits and dogs, so that the ethanol content in the blood of the rabbits is quickly reduced. The ginsenoside can resist the inhibiting effect of malonate on dehydrosuccinic acid, and the ginsenoside has effects of resisting and relieving liver injury, vascular wall connective tissue hyperplasia and increased transhistidine caused by carbon tetrachloride, and has effect of enhancing liver detoxification function. The action of the ginseng is related to that the ginseng can enhance the activity of alcohol dehydrogenase, succinate dehydrogenase, glutathione transferase, malate dehydrogenase and RNA polymerase in liver and enhance the oxidative phosphorylation process in liver cell microsome.
2.8.2 protective action against gastric mucosal Damage
The panaxaline polysaccharide component GRA-2 has inhibitory effect on gastric mucosa injury caused by hydrochloric acid or ethanol, with inhibition rates of 57.3% and 74.1%, respectively, and has certain protection effect on gastric mucosa.
(II) Glycyrrhiza uralensis
1 traditional medicine property
1.1 the properties, flavor and meridian tropism
Sweet in flavor and neutral in nature. It enters heart, spleen and stomach meridians.
1.2 mechanism of function
Li Shizhen reviewed the pharmacological discussion of the properties of Licorice root in Ben Cao gang mu by physicians of all generations, he summarized Licorice root indications: the five zang-organs and six fu-organs have the effects of strengthening muscles and bones, growing muscle, strengthening strength, treating carbuncle, removing toxic materials, reducing weight and prolonging life after long-term use. "Ben Cao Jing" (the book of materia Medica) … … unprocessed for purging fire and heat, cooked for dispelling exterior cold, relieving pharyngalgia, removing pathogenic heat, relieving healthy qi, nourishing yin and blood, invigorating spleen and stomach, and moistening lung ".
2 modern pharmacological research
2.1 Effect on digestive System
2.1.1 anti-gastric ulcer Effect
Glycyrrhizin and glycyrrhetinic acid derivative gastrinone (18-beta-glycyrrhetinic acid hemisuccinate disodium salt) have certain gastric ulcer resisting effect.
2.1.2 spasmolytic action
TM100The flavone compounds such as isoliquiritigenin can also relieve BaCI2And intestinal spasm caused by histamine and isoliquiritigenin also have strong spasmolytic effect on intestinal smooth muscle.
2.1.3 hepatoprotective effects
Oral administration of glycyrrhizic extract and licoflavone to carbon tetrachloride (CCI)4) The induced liver injury of the rat has obvious protective effect, can obviously reduce the degree of degeneration and necrosis of liver tissues, and recovers the regeneration and synthesis functions of glycogen and ribonucleic acid in liver cells. The activities of serum glutamic acid alanine and lactic acid dehydrogen acid are obviously reduced, and the licorice flavonoids have protective effect on the liver injury of mice caused by ethanol, and obviously inhibit the increase of the content of malondialdehyde in liver tissues and the exhaustion of reductive glutathione. It is also thought that glycyrrhetinic acid has liver protecting effect and can antagonize cell lipid peroxidation and inhibit Ca2+And the flow into the cells.
2.2 Effect on immune System function
2.2.1 enhancement of nonspecific immune function
The glycyrrhizin is 25mg/kg, and can be administered by abdominal cavity, so as to obviously improve clearance index of mice to intravenous injection carbon granules, and can stimulate phagocytosis of macrophages at low concentration. Glycyrrhiza polysaccharide, glycyrrhizin UA, UB, UC also have obvious activating effect on reticuloendothelial system.
2.2.2 enhancement of specific immune function
Glycyrrhizic acid at a certain concentration can promote the production of polyclonal antibodies, and the increase of antibody production is related to the increase of IL-1 production. Glycyrrhizin also increases the levels of gamma interferon (γ -IFN) production by spleen cells induced by ComA. 100mg/kg of glycine oxalate can also be administered for 7 days to make mouse spleen Prostaglandin (PGE)2) And a significant increase in the amount of CAMF. Rat lymphocytes can also obviously increase the secretion of PGE under the action of glycyrrhizin. The liquorice and the extract thereof have certain regulation effect on the body immunologic function.
2.2.3 antiallergic action
Glycyrrhizin can obviously inhibit passive skin allergic reaction of mice, antagonize histamine, LXAnd slow-reacting substance contraction of isolated ileum rabbit and isolated tracheal smooth muscle of guinea pig. The antiallergic effect of liquorice is one of the main manifestations of corticoid-like effect. The effect and the ability to inhibit phosphatidic acid A2Activity, thereby inhibiting PGE2The CAMP concentration is increased, and the release of active substances such as histamine is prevented; reduction of tissue cell pair PGE2Reactivity of active factors such as MIF (macrophage migration inhibitory factor) and the like, and inhibition of antibody production.
2.3 Effect on the Central nervous System
Glycyrrhetinic acid (125mg/kg) and paeoniflorin can induce sedative effect and hypnotic effect on mice. FM100Has tranquilizing effect and also has effect in inhibiting convulsion caused by pentylenetetrazol. Glycyrrhetinic acid and glycyrrhizin have antipyretic effects of different degrees on heat-producing rat, mouse and rabbit.
2.4 Effect on the cardiovascular System
2.4.1 Effect on the Heart
The decoction of radix Glycyrrhizae can increase the amplitude of systole of Bufo siccus in vitro. The glycyrrhizin can excite the isolated heart of the toad and has obvious synergistic effect with epinephrine; it also has effect in resisting the inhibition of acetylcholine (Ach) and physostigmine on heart.
2.4.2 antiarrhythmic action
The radix Glycyrrhizae Preparata extract crude drug 1g/kg is administered intravenously, and has inhibitory effect on aconitine-induced ectopic rhythm and supraventricular arrhythmia, and the glycyrrhetinic acid 18- β has different degrees of inhibitory effects on chloroform-induced ventricular fibrillation of mouse and chloroform-induced supraventricular arrhythmia of rabbit, and can also make CaCI2The time to the onset of induced supraventricular arrhythmias is significantly prolonged in rats.
2.4.3 hypolipidemic Effect
The blood lipid reducing effect of glycyrrhizin is related to administration dosage, and at the dosage of 2mg/kg, the blood plasma cholesterol content of the rabbit with ventricular atherosclerosis can be reduced, and the development of the arteriosclerosis of the aorta and the coronary artery can be prevented. When the dosage is 10mg/kg, the contents of cholesterol and triglyceride in the blood plasma of the experimental hyperlipoidemia rabbits can be obviously reduced. The dose was 40mg/kg, but not effective.
2.4.4 antiplatelet aggregation Effect
3-aromatic coumarin derivative GU-7 separated from Glycyrrhrizae radix has obvious effect in inhibiting platelet aggregation.
2.5 Effect on the respiratory System
2.5.1 antitussive effect
Licoflavone, Glycyrrhrizae radix extract and glycyrrhetinic acid all have obvious inhibiting effect on mouse cough caused by ammonia water and sulfur dioxide. Glycyrrhetinic acid with strongest effect and cholate contained in Glycyrrhrizae radix are injected subcutaneously at a dose of 1mg/kg, and have a cough suppression rate of 80%, and the antitussive effect is different from hydrocortisone and is generated through central nerve.
2.5.2 phlegm eliminating action
Licoflavone, Glycyrrhrizae radix extract and glycyrrhetinic acid not only have antitussive effect, but also have good expectorant effect, and Glycyrrhrizae radix can promote secretion of throat and bronchus, so that phlegm can be easily expectorated.
2.5.3 antiasthmatic action
Intraperitoneal injection of licorice decoction or licorice extract Lx66The reduction of β -receptor reactivity and the reduction of β -receptor number caused by repeated application of isoproterenol can be prevented, which indicates that the liquorice has certain effect of relieving asthma.
2.6 detoxification action
2.6.1 detoxification of chemical substances
The glycyrrhiza extract and glycyrrhizin have obvious detoxification effect on the toxicity of substances such as strychnine, urethane, cocaine, arsenic phenoxide, ascending pump and the like. The liquorice decoction has the second detoxifying effect on the toxin of the printed defense, the caffeine, the acetylcholine, the pilocarpine, the nicotine and the barbital, and can effectively weaken the toxicity of the dichlorvos, so that the toxic and death percentage of mice is obviously reduced.
2.6.2 detoxification and potentiation
The glycyrrhizin, the anticancer drugs camptothecin and the agricillin have the functions of detoxification and synergism, and the glycyrrhizic acid monoammonium salt can obviously resist the toxicity of the camptothecin and enhance the antitumor effect. Is related to that licorice has corticoid-like action and improves the tolerance of the organism to toxicants, and also can obviously improve the liver cytochrome P-450The content of (b) is related to the induction of detoxification of liver enzymes.
2.7 anti-inflammatory action
The anti-inflammatory effect of licorice is related to the effect of licorice on the biological oxidation process of cell and the reduction of sensitivity of cell to inflammatory reaction substance. The flavone component in Glycyrrhrizae radix can obviously inhibit the generation of 5-HETE, 12-diheTE, 12-HETE, etc. of arachidonic acid metabolite of leukocyte and platelet, inhibit the release of lysosome enzyme from leukocyte, increase CAMP concentration to prevent the release of histamine, etc., and inhibit the association of degranulation reaction.
2.8 antibacterial and antiviral action
2.8.1 antibacterial action
The licorice extract and sodium glycyrrhetate can inhibit staphylococcus aureus, tubercle bacillus, colibacillus, amoeba protozoon and trichomonad in vitro, 18- β sodium glycyrrhetate can inhibit staphylococcus aureus and bacillus subtilis G+Has obvious inhibition effect with bacillus.
2.8.2 antiviral action
Glycyrrhizin can inhibit the proliferation of more than 98% of AIDS virus at a concentration of 0.5 mg/ml; the glycyrrhiza polysaccharide has inhibitory effect on vesicular stomatitis virus, adenovirus type III, herpes simplex virus type I, vaccinia virus, etc., and can significantly inhibit the incidence of cytopathic effect, so that the cells cultured by the tissue are maintained.
2.9 other effects
2.9.1 Oxidation resistance
Licoflavone (FG) can obviously inhibit the increase of malondialdehyde in liver homogenate of mice when the dosage is 2.5-25 μ g/ml, and has obvious scavenging effect on alkaline dimethyl sulfoxide, oxygen free radicals generated by xanthine oxidase and oxygen free radicals and hydroxyl free radicals released by polyamine cells stimulated by PMA when the dosage is 0.265-26.5 μ g/ml or 2.58-258 μ g/ml.
2.9.2 antidiuretic action
Glycyrrhizin can significantly reduce urine volume in rats accompanied by Na+Decrease in discharge amount of (K)+The discharge amount of (2) is also reduced. After the adrenal gland of the rat is cut off, the glycyrrhizin can still enable Na+、K+The discharge amount is reduced. Glycyrrhetinic acid and its salt also have remarkable diuretic effect.
2.9.3 Effect on Estrogen
Glycyrrhizin and glycyrrhetinic acid can inhibit the growth of estrogen on uterus of immature animals, and the same effect can be obtained after adrenal gland and ovary are removed.
2.9.4 antitumor effect
Glycyrrhizin has obvious inhibition effect on rat precancerous lesion caused by diethylnitrosamine.
(III) Amomum fruit
1 traditional medicine property
1.1 the properties, flavor and meridian tropism
Pungent taste and warm nature. It enters spleen and stomach meridians.
1.2 mechanism of function
1.2.1 moving qi and regulating the middle warmer, stimulating appetite and promoting digestion.
The herbal books from Tang Dynasty all record the property of Sha ren to promote flow of qi, regulate the middle warmer, stimulate the appetite and promote digestion. For example, in materia Medica of drug property: "Xiaohua Gu and Zhi Cold-wind abdominal pain". Compendium of materia Medica: the traditional Chinese medicine has the effects of warming spleen and stomach, ascending qi and cough, playing the flavor of wine, regulating the middle warmer and promoting qi circulation and treating qi stagnation of spleen and stomach. Tonifying lung and spleen, nourishing stomach and kidney, regulating primordial qi, dredging qi, dispelling cold, relieving distension and fullness, and relieving dysphagia and emesis … … ".
1.2.2 warming spleen to stop diarrhea
Many books record the spleen-warming and diarrhea-checking functions of Sha ren, as in Kai Bao Ben Cao (materia Medica of Kai): it is indicated for dysentery with red and white discharge, abdominal pain due to deficiency. The herbal Zhenzhen: it is effective in treating dysentery with red and white color when entering large intestine. In a word, Sha ren is pungent in flavor, warm in property, resolve dampness, activate spleen and invigorate stomach, so it is mainly indicated for spleen, and it is indicated for deficiency-cold of spleen and stomach.
2 modern pharmacological research
2.1 Effect on the nervous System
Through intragastric administration, the disappearance and recovery of the righting reflex are regarded as the sleep time, and the fructus amomi is found to be capable of obviously shortening the sleep time of mice induced by the pentobarbital sodium. The amomum fruit and the indomethacin have obvious synergistic effect on the inhibition of the mouse central nervous system caused by the sodium pentobarbital.
2.2 Effect on digestive System
The fructus amomi has the effect of resisting stress ulcer of a mouse, can obviously increase gastric acid secretion activity and pepsin activity of the rat, and the fructus amomi leaf oil can prevent the formation of pyloric ligation ulcer of the rat, but the anti-ulcer effect of the fructus amomi leaf oil has no obvious relation with gastric acid secretion. The amomum fruit leaf oil also has obvious inhibiting effect on the movement of isolated ileum of rabbits and guinea pigs, has obvious relaxing effect on spastic contraction caused by barium chloride, acetylcholine and histamine phosphate, can completely block the isolated intestinal spasm of rabbits caused by barium chloride, and partially blocks the isolated intestinal spasm of rabbits caused by acetylcholine and histamine phosphate. After the fructus amomi is irrigated to a mouse for 40min, compared with a control group, the moving distance of the activated carbon in the gastrointestinal tract is obviously different, and the fructus amomi is proved to have the function of promoting gastrointestinal peristalsis.
2.3 Effect on platelet aggregation function
The fructus amomi suspension has obvious inhibiting effect on ADP-induced rabbit platelet aggregation, and the action time is prolonged along with the increase of the dosage. The fructus amomi suspension has obvious protective effect on the acute death of mice induced by arachidonic acid or a mixture of collagen and adrenaline.
2.4 Effect on the immune System
When PFC is measured by a polystyrene plate method, the fructus amomi has the effect of obviously inhibiting mouse antibody from forming cells.
2.5 Effect on the liver
The fructus Amomi water extract can increase liver coefficient of mouse, and homogenize liver cell factor P450The content has no obvious influence.
(IV) Lily bulb
1 traditional medicine property
1.1 the properties, flavor and meridian tropism
Sweet and slightly cold. It enters heart and lung meridians.
1.2 mechanism of function
1.2.1 moistening lung to arrest cough, it is used for cough due to lung heat, cough due to overstrain, hemoptysis, chronic cough due to lung heat with bloody sputum, and combined with coltsfoot flower.
1.2.2 it has effects of clearing away heart-fire and tranquilizing mind, and can be used for treating absentmindedness, language, action, diet, sensory disturbance, bitter taste, and dark urine.
1.2.3 for lung pain, the lily bulb is singly used and cooked or steamed.
1.2.4 it is used for treating atrophic gastritis, and is prepared from Bulbus Lilii, radix Paeoniae alba, radix astragali, and radix Glycyrrhizae.
1.2.5 can be used for treating neurasthenia or climacteric syndrome, and is cooked with Bulbus Lilii and semen Ziziphi Spinosae.
[ Ezeria ] lily is sweet and moist, can tonify, moisten lung to arrest cough, clear heart fire and tranquilize mind. It is sweet in flavor and tonifying, cold in property and clearing heat, entering heart and lung meridians, so it has the actions of moistening lung to stop cough, clearing heart fire and tranquilizing. The product can be used as both medicine and food, has bitter and cold properties, and can be used for treating lung dryness, dry cough, cough with excessive consumption, hematemesis, and late stage of fever, vexation, palpitation, insomnia, dreaminess, and listlessness, and has effects of health promotion and life prolonging.
2 modern pharmacological research
2.1, components: bulbus Lilii contains hydrolyzed colchicine, starch, protein, fat, sugar, calcium, phosphorus, and iron.
2.2 pharmacological study: the decoction has effects in relieving mouse cough caused by ammonia water, relieving toad asthma caused by tissue ammonia, preventing leukopenia caused by cyclophosphamide, and inducing estrogen-like action.
Second, processing of health preserving medicinal preparation
A health preserving pharmaceutical preparation comprising: 20 parts of ginseng, 35 parts of lily, 25 parts of fructus amomi and 20 parts of liquorice.
The ginseng and the fructus amomi are washed by water, dried, respectively crushed into superfine powder and sieved by a 400-mesh sieve to obtain ginseng powder and fructus amomi powder for later use.
Soaking lily and licorice in water for 3 hr, with the water amount being 5 times of the total weight of lily and licorice; after soaking, using a traditional baked earthen jar as a decocting container, decocting for 1 hour by slow fire in the decocting process, stopping decocting when the amount of the decoction is 15% of the amount of the added water, separating out the decoction, adding water into the decoction dregs again for decocting, wherein the decocting condition is the same as that of the first decocting, and mixing the decoction obtained in the second decocting with the decoction obtained in the first decocting.
Concentrating the obtained medicinal juice to obtain extract, adding the obtained Ginseng radix powder and fructus Amomi powder, mixing, and vacuum drying at a temperature below 50 deg.C to obtain granule preparation.
Third, record of clinical treatment data of health preserving pharmaceutical preparation
The treatment data of the health preserving pharmaceutical preparation are shown in table 1.
TABLE 1 clinical treatment data for health preserving pharmaceutical preparations
The details of the situations before and after taking by a plurality of patients with the health-preserving medicinal preparation are listed as follows: (the product is a health preserving medicine granule preparation prepared by the scheme, 6g of the preparation is taken in each bag with warm water)
1. The tumor postoperative radiotherapy and chemotherapy period patients:
case 1: mr. prune, male, age 65. The disease is characterized in that the disease is cured in the east of living areas of a combined fertilization and chemical plant, the disease has a smoking history of more than 40 years, the disease is cured by white sticky plague after getting up in the morning for a long time, the outbreak of external infection continues to be expectorated continuously in the last ten days of 3 months in 2011, the disease is aggravated at night, blood streaks are contained in sputum in the morning, antiviral and antibacterial drugs are taken orally and are used together for treatment for two weeks, the symptoms are improved to some extent, the chest and the back are dull and oppressed, the fatigue, the dry mouth and the inappetence continue to appear, the department of hospital is transferred to the province, the middle lobe of the right lung and the upper lobe of the left lung respectively show irregular infiltration shadows, the adenocarcinoma is diagnosed by the examination. Patients are emaciation, poor sleep, dry sputum with little sputum, chest distress, palpitation, hypodynamia, spontaneous perspiration, dry mouth, only eating semifluid diet and unsmooth defecation. The health-preserving medicinal preparation is orally taken 2 hours after breakfast and supper, one bag is respectively taken with warm boiled water, the conscious sleep is improved after one week, the chest distress and palpitation are relieved, a little white phlegm, hypodynamia, spontaneous perspiration are improved, the mouth is dry, half bowl of soft rice can be eaten, the soft rice can be put down to a bed to brush teeth and wash faces, the people can walk at home slowly, and the defecating is smooth. After being taken continuously, the diseases disappear after one year, no tumor relapse is seen through lung CT double diagnosis, and the life is still healthy.
Case 2: old women, 51 years old, live in the province and the Living hall dormitory of Anhui Hui. In 10 months of 1989, the patient feels aversion to cold, is worried and irritative in the afternoon, has poor sleep, starts in the morning, is dry and bitter in mouth, has reduced meal volume and is reduced in weight because the left breast is distended and painful and the nipple is itchy and yellow brown liquid. Go to the outpatient department of mammary gland department in the institute of Security and medical science, confirm the diagnosis of the middle stage of breast cancer through the biopsy and discharge through the operation and chemotherapy. The patients have dull complexion, alopecia, marasmus, insomnia, and difficulty in eating rice water or batter, and have symptoms of stomach pain and distention, morning fatigue, nausea, emesis, dry mouth, poor drinking water, and asthenia. The product is administered with warm boiled water in the morning for one bag; A bag is drunk 2 hours after meal. Nausea in the morning after one week, and vomiting after meal. The thirst is improved, and the nausea is avoided after drinking 300 ml of warm boiled water before and after each meal, and people want to eat the cooked rice. After two weeks, the user can sleep for 3 hours at night after the sleep is improved, the discomfort of stomach dull pain and fullness is improved, and the user can walk slowly. After one month, the flour becomes moist and has better spirit, the stomach discomfort is greatly reduced after sleeping for about 5 hours, and one bowl of porridge and one egg in the morning are eaten separately; adding a bowl of soup and dish in half a bowl of rice at noon; and a small bowl of noodles at night. It is healthy up to now.
2. Diabetic type ii patients:
case 1: mr. Tang Dynasty, 47 years old, Yifei Forklift sales company stay outside manager, 6 months dizziness, palpitation, soreness and weakness of waist and knees, easy hunger, thirst, spontaneous perspiration, easy waking up at night can not fall asleep for more than two years, through the tests of blood test, electrocardio and B ultrasonic examination in the department of endocrinology of the department of medical university and institute of medical university, the diagnosis of diabetes type II and insulin insufficiency are confirmed, insulin and metformin are adopted for oral sugar control treatment for one year, the patient still feels tired and weak, has meals, exercise and frequent spontaneous perspiration at night, the patient has a dry mouth after morning and meals, the patient has a heavy drink, the patient is easy to starve, feel distending in the stomach, feeling the stomach, and feeling fullness after meals, the stomach is full of belching, the stool is dry and uneven, and turbid urine foams are many. The product is taken with warm boiled water 2 hours before breakfast and after dinner every day. Sleep is improved at night after one week, after a meal, stomach fullness and warm air are better, thirst is relieved, and fatigue, spontaneous perspiration and abnormal stool are better. After drinking for one year, all symptoms disappear.
Case 2: zhao women, 39 years old, get fat to the adult train conductor. In 2016, palpitation, chest distress in 5 months, poor sleep (about 3 hours), dysphoria, thirst, polydipsia, anorexia, tiredness, hypomenorrhea, and loose stool. The syndrome of diabetes mellitus ll type, deficiency of both heart and spleen and dysfunction of spleen and stomach are confirmed by the auxiliary hospital physical examination of Anhui Chinese medicine university. The oral liquid of metformin and radix astragali is administered for one year. Blood sugar control is unstable, the stomach is still distended and uncomfortable, fatigue, dry mouth and thick stool occur in the morning, sleep is still poor at night, tiredness occurs in the morning, and the menstrual flow is the same as before. The product is taken with warm boiled water in the morning and 2 hours after supper. After one week, people feel sleepy after 10 hours, if the people are not in a car, the people can sleep for about 4 hours at home, fatigue is relieved in the morning, dry mouth is relieved, and after lunch or dinner, stomach fullness and warm air are relieved, and stool consistency is improved. After one month, the patient feels moist, has a palpitation and chest distress improving effect, is good in sleep and fatigue, has a stomach fullness and discomfort, relieves the heat, has a large dry mouth, obviously improves appetite, has a soft, non-sticky and smooth stool shape, and slightly increases the menstrual flow by one day and is red. The blood sugar is stable in the morning and at night after being continuously drunk for one year, and all symptoms disappear.
3. Sub-health syndrome user:
case 1: song classmate, male, 24 years old, university of Chinese science and technology, biological system research student. In 8 months in 2019, the glasses are broken once when the user sleeps in the morning and goes to an experimental class, the root of the nose is scratched, and the test tube which is not taken stably falls and is broken once. The oral cavity is dry and the drinking is favored all day long, the mouth and tongue are sore and painful intermittently, the halitosis, the stomach dull pain is accompanied with burning sensation, the fullness and discomfort after eating are caused, the hair is washed and the hair loss is more before half a year, the white bits and the pruritus of the skin of the limbs and the back are generated before the spring festival for more than four months, and the improvement is realized only in summer. In life, breakfast is rarely eaten, people are hot and heavy in mouth, and sleep from early middle school to 1 o' clock at midnight. The health-preserving medicinal preparation is taken with warm boiled water for 2 hours after being taken with an empty stomach and in the morning. One week later, drowsiness, dry mouth, upset stomach, and appetite improvement. The symptoms disappear after the drinking for three months.
Case 2: korean female, 29 years old, Yili Si Geba entertainment city leading manager. In 2017, the patient is diagnosed with long-term fatigue, alopecia, dry mouth, repeated attack of aphtha, pain, skin dryness and pruritus in nearly two months and amenorrhea for three months. The patients have a dull complexion, chloasma on the forehead and the cheeks on the right cheeks, pale lips, pale and swollen tongue, white and dry fur, and deep, thready and rapid pulse. The health-preserving medicinal preparation is drunk in a bag with warm boiled water respectively in an empty stomach in the morning and 2 hours after supper, the conscious spirit is obviously improved after one week, and the skin is dry and the itch, the mouth is dry, and the mouth sore pain is relieved. The three-month re-diagnosis is continued to be drunk, the menstruation is recovered, and the rest symptoms disappear.
4. The patients with cough and asthma:
case 1: mr. Meng, 58 years old, was once a warehouse manager of the combined fertilizer and meat factory, and was responsible for the work of delivering and warehousing the cold storage food. Cough and asthma secondary to heatstroke in 6 months of 1986, white and sticky cough with little foam phlegm, palpitation, chest distress and discomfort, frequent occurrence in winter and spring, aggravation of cough and asthma at night, spontaneous perspiration, fatigue, hypodynamia, inappetence and dry stool. When the doctor is in the clinic, the back of the bow is in the consulting room, the face is yellow, the lips are dark purple, the tongue is pale, the tongue tip is petechia, the coating is thin and dry, and the pulse is deficient and unsmooth. The health-preserving medicinal preparation is taken with warm boiled water one bag each in morning on an empty stomach and hours after meals. One week later, the patient feels palpitation and chest distress is relieved, appetite is increased, and the mouth dryness and dry stool are improved. After drinking for a year, the cough and asthma time is obviously shortened in winter and spring today, little expectoration is easy to be expectorated, and the usual time is basically the same as that of a normal person.
Case 2: liu women, 41 years old, Anhui Jiatong tire company quality inspector. In 2013, the patient is cured by western medicine infusion treatment due to upper respiratory tract infection with fever and yellow sticky phlegm with chest distress and discomfort in 11 months. But the cough in the morning and at night is a few sounds, and a little white sticky phlegm is cough. Cough in 3 months in 2014 obviously increases the symptoms of chest distress with asthma, obvious feeling of gradual sweating of the back during cough, sweating at the head during eating, spontaneous sweating during sleeping, dry mouth and nose in the morning, and good appetite, hypodynamia and dry stool. The face is lusterless, the lips are pale white, the tongue is thin and dry, the coating is thin and dry, and the pulse is weak. The product is administered after breakfast and fasting in the morning and supper, and is taken with warm boiled water. After one week, the feeling of chest oppression is relieved, the mouth and the nasal cavity are moistened, the appetite is increased, the spirit is good, and the cough is reduced. The beverage can be drunk for one year. All symptoms disappear.
5. Patients with chronic gastritis and gastric ulcer:
case 1: pengsheng, 37 years old, Anhui Zhongqi group taxi company taxi drivers. Half of the iced watermelons are eaten after work in 9 months in 2012 because of hot weather, the hearts of the stomach occur after one week, nausea occurs when teeth are brushed in the morning, dull pain in the stomach gradually occurs, the hearts burn before meals, and the people feel distending pain and discomfort after meals, and the weight is reduced, tired and poor in sleep after one year. The patients have poor spirit, emaciation, yellow complexion, white and moist coating, and deep, slow and astringent pulse. The health-preserving medicinal preparation is taken with warm boiled water one bag each in morning on an empty stomach and hours after meals. One week later, the user does not feel tired when driving the toothbrush, and the nausea and heartburn of the toothbrush are relieved in the morning, so that the stomach is relieved from dull pain and fullness. After drinking for three months, all symptoms disappear.
Case 2: a lady, 26 years old, a joint-fatness, Shunfeng express company clerk. In 2018, the patient often can not eat the food on time due to busy business, and the patient is diagnosed with gastric ulcer by stomach spasm and pain accompanied by vomit due to sudden fatigue, secondary dizziness and black asphalt excrement hospitalization. The patients have pale complexion, pale lips, anemia, dry tongue with little body fluid, and weak and soft pulse. The health-preserving medicinal preparation is taken with warm boiled water one bag each in morning on an empty stomach and hours after meals. After one week, dizziness is improved, spirit is improved, and the patient can be healed after drinking for one month.
6. The patients who are drunk with alcoholic liver:
case 1: mr. Wang, 53 years old, Anhui electric company service department manager. In 2007, chronic cholecystitis, gastritis and alcoholic hepatitis can be detected in the first hospital in the mixed fertilizer market due to vague pain, hypodynamia, inappetence, dry mouth, bitter taste and insomnia on the right side in 6 months. The patients have a dark purple complexion, dry lips, halitosis, red tongue, thin yellow and dry coating, and deep and soft pulse. The health-preserving medicinal preparation is taken in a bag with warm boiled water in the morning and 2 hours after meals. After one week, the patient feels better sleep, and the patient suffers from hypodynamia, dull pain in the right upper abdomen, dry mouth and inappetence. After drinking for three months, all symptoms disappear.
Case 2: ginger women, 38 years old, Anhui Gujing tribute wine, and manager of the Ministry of the Fertilizer market. In the long-term drinking history in 7 months in 2018, chronic gastritis and alcoholic hepatitis are confirmed and diagnosed by the physical examination in the hospital 901 of the liberation army due to dizziness, memory decline, vision decline, dry eyes, astringency and pain, stomach distension, upset, inappetence and easy fatigue. In the clinic, there are lusterless complexion, chloasma on the left and right cheeks, pale purple lips, thin and red tongue with thin, yellow, dry and scanty saliva coating, and deep and deficient pulse. The health-preserving medicinal preparation is taken with warm boiled water for one bag in the morning and evening and hours after meal. After one week, the face turns moist, the stomach is noisy, the appetite is not improved, the dry mouth is relieved, and the spirit is improved. After drinking for three months, all symptoms disappear.
According to the clinical treatment data and records, the health-care medicinal preparation prepared and processed by the scheme is suitable for long-term dietary therapy conditioning of the crowd with tumor postoperative radiotherapy and chemotherapy, diabetes type II, chronic cough and asthma, long-term stay-up sub-health syndrome, chronic gastritis, gastric ulcer, alcoholism and alcoholic liver. The medicine has no side effect and no dependence, is a health-preserving health-care medicine which is taken by the majority of people for a long time and has no disease and no consideration for the disease.
Claims (8)
1. A health preserving pharmaceutical preparation is characterized in that: the composition comprises the following components in parts by weight: 15-30 parts of ginseng, 20-50 parts of lily, 10-40 parts of fructus amomi and 15-30 parts of liquorice.
2. A method for processing the health preserving pharmaceutical formulation as claimed in claim 1, comprising the steps of:
(1) respectively pulverizing Ginseng radix and fructus Amomi, and sieving with 400 mesh sieve to obtain Ginseng radix powder and fructus Amomi powder;
(2) decocting Bulbus Lilii and Glycyrrhrizae radix in water to obtain decoction;
(3) concentrating the medicinal juice obtained in the step (2) into an extract, adding the ginseng powder and the fructus amomi powder obtained in the step (1), uniformly mixing, and drying at low temperature to obtain the granular medicine, namely the health-preserving medicinal preparation.
3. The method for processing a health preserving pharmaceutical preparation according to claim 2, characterized in that: in the step (1), the ginseng and the fructus amomi are washed by water and dried before being crushed.
4. The method for processing a health preserving pharmaceutical preparation according to claim 2, characterized in that: in the step (2), before the decoction in water, the lily and the liquorice are soaked in water for 2-4 hours, and the water adding amount is 4-6 times of the total mass of the lily and the liquorice.
5. The method for processing a health preserving pharmaceutical preparation according to claim 2, characterized in that: in the step (2), the decoction water is water in the soaking process.
6. The method for processing a health preserving pharmaceutical preparation according to claim 2, characterized in that: in the step (2), a crock is used as a decocting container, slow fire is adopted for decocting for 1-1.5 hours in the decocting process, the decocting is stopped when the amount of the decoction is 10-20% of the amount of the added water in the decocting process, and the decoction is separated.
7. The method for processing a health preserving pharmaceutical preparation according to claim 2, characterized in that: in the step (2), the decoction process is carried out twice, after the first decoction is finished and the decoction is separated out, 4-6 times of water by mass is added into the medicine residues, the decoction process is repeated, and the decoction which is separated out for the second decoction is mixed with the decoction which is obtained by the first decoction.
8. The method for processing a health preserving pharmaceutical preparation according to claim 2, characterized in that: in the step (3), the low-temperature drying is vacuum drying in a low-temperature environment of less than 50 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010718655.8A CN111643631A (en) | 2020-07-23 | 2020-07-23 | A health-preserving medicinal preparation and its processing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010718655.8A CN111643631A (en) | 2020-07-23 | 2020-07-23 | A health-preserving medicinal preparation and its processing method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111643631A true CN111643631A (en) | 2020-09-11 |
Family
ID=72350236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010718655.8A Pending CN111643631A (en) | 2020-07-23 | 2020-07-23 | A health-preserving medicinal preparation and its processing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111643631A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1091918A (en) * | 1993-03-10 | 1994-09-14 | 马杰 | Ginseng serial health nourishing can |
CN1439280A (en) * | 2002-02-22 | 2003-09-03 | 刘凤鸣 | Candy with caffeine |
-
2020
- 2020-07-23 CN CN202010718655.8A patent/CN111643631A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1091918A (en) * | 1993-03-10 | 1994-09-14 | 马杰 | Ginseng serial health nourishing can |
CN1439280A (en) * | 2002-02-22 | 2003-09-03 | 刘凤鸣 | Candy with caffeine |
Non-Patent Citations (2)
Title |
---|
方山: "《人参》", 30 June 1999, 南方出版社 * |
路臻等: "《中草药抗癌速查手册》", 31 January 2017, 山西科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
CN101797326A (en) | Chinese materia medica preparation for treating borborygmus diarrhoea and preparation method thereof | |
CN102205108B (en) | Traditional Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
CN103719491B (en) | A kind of sealwort invigorating the spleen moistening lung health protection tea and preparation method thereof | |
CN104824293A (en) | Preparation method of anti-insomnia substitutional tea prepared by adopting edible plants as ingredients | |
CN111249420A (en) | Traditional Chinese medicine composition for regulating and treating qi-stagnation constitution and preparation and application thereof | |
CN114748603B (en) | Pharmaceutical composition for preventing and treating new coronavirus pneumonia from changing or restoring yang and application thereof | |
CN104824292A (en) | Anti-insomnia substitutional tea made by adopting edible plants as ingredients | |
TW202330006A (en) | Composition for preventing, improving or alleviating symptoms relating to qi deficiency and/or blood deficiency | |
CN118434431A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
CN111643631A (en) | A health-preserving medicinal preparation and its processing method | |
CN102671058B (en) | Traditional Chinese medicine oral liquid for treatment of vomiting and preparation method thereof | |
CN116549595B (en) | Pharmaceutical composition for treating functional dyspepsia of children, preparation and application thereof | |
CN105079391A (en) | Effervescent tablets for preventing oral ulcer and preparation method therefor | |
CN110859949A (en) | Traditional Chinese medicine composition for treating infantile transient tic disorder and preparation method and application thereof | |
CN115737777B (en) | Compound anti-alcohol traditional Chinese medicine composition and preparation method thereof | |
CN102641442B (en) | Traditional Chinese medicine preparation for treating recurrent aphthae | |
CN105125985A (en) | Chinese and western medicine compound preparation for treating senile chronic bronchitis and preparation method thereof | |
CN106309901A (en) | Radix scrophulariae buccal tablets and preparation method thereof | |
CN115957158A (en) | Composition for improving pigmentation, fading spots and whitening skin and preparation method and application thereof | |
CN105343567B (en) | Infant sleep-promoting formula | |
WO2023189035A1 (en) | Composition for preventing, improving, or mitigating kidney-deficiency-associated symptoms or conditions of skin, hair, and nails | |
CN103637349B (en) | Functional beverage capable of removing dampness and tonifying deficiency and preparation method thereof | |
KR20020044378A (en) | Made for healthy food using of Acanthopanax sessiliflorus, Prunus mume, Ganoderma lucidum and Erigeron canadensis | |
CN117205273A (en) | Chinese patent medicine for resisting AIDS and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200911 |